HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gerald W Hart Selected Research

Hexosamines

5/2016New insights: A role for O-GlcNAcylation in diabetic complications.
4/2014The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.
1/2006Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells.
6/2005O-GlcNAc modification of nucleocytoplasmic proteins and diabetes.
4/2002Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gerald W Hart Research Topics

Disease

11Insulin Resistance
08/2013 - 04/2002
7Hyperglycemia
05/2016 - 04/2002
7Alzheimer Disease (Alzheimer's Disease)
05/2012 - 01/2003
5Diabetes Complications
05/2016 - 06/2005
5Neoplasms (Cancer)
03/2014 - 02/2010
5Neurodegenerative Diseases (Neurodegenerative Disease)
03/2014 - 02/2010
3Type 2 Diabetes Mellitus (MODY)
11/2019 - 02/2007
2Inflammation (Inflammations)
10/2016 - 10/2008
2Diabetic Nephropathies (Diabetic Nephropathy)
09/2011 - 01/2006
2Polyploidy
01/2010 - 09/2005
2Neuroblastoma
12/2008 - 05/2008
1Atrial Fibrillation
01/2021
1Cardiomyopathies (Cardiomyopathy)
01/2016
1Diabetic Cardiomyopathies
01/2016
1Diabetic Retinopathy (Retinopathy, Diabetic)
04/2014
1Blindness (Hysterical Blindness)
04/2014
1Vision Disorders (Hemeralopia)
04/2014
1Chronic Disease (Chronic Diseases)
03/2014
1Heart Failure
10/2013
1Diabetes Mellitus
10/2013
1Acquired Immunodeficiency Syndrome (AIDS)
02/2010
1Ischemia
05/2008
1Parkinson Disease (Parkinson's Disease)
02/2008
1Hyperlipidemias (Hyperlipidemia)
11/2007
1Hyperinsulinism (Hyperinsulinemia)
11/2007
1Hypoglycemia (Reactive Hypoglycemia)
11/2007
1Tauopathies
07/2004
1Lymphoma (Lymphomas)
05/2002

Drug/Important Bio-Agent (IBA)

18Proteins (Proteins, Gene)FDA Link
11/2019 - 04/2002
13Glucose (Dextrose)FDA LinkGeneric
05/2016 - 04/2002
5HexosaminesIBA
05/2016 - 04/2002
5AcetylglucosamineIBA
04/2014 - 05/2002
3O-GlcNAc transferaseIBA
01/2010 - 09/2005
2Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
01/2021 - 10/2013
2Transcription Factors (Transcription Factor)IBA
10/2016 - 01/2011
2hexosaminidase CIBA
07/2010 - 01/2003
2EnzymesIBA
01/2010 - 09/2005
2Insulin (Novolin)FDA Link
11/2007 - 04/2002
1CytokinesIBA
10/2016
1Ion Channels (Ion Channel)IBA
10/2013
1ActininIBA
09/2011
1ChromatinIBA
01/2011
1Deubiquitinating EnzymesIBA
11/2010
1Polysaccharides (Glycans)IBA
10/2008
1Dopamine (Intropin)FDA LinkGeneric
02/2008
1Amyloid beta-PeptidesIBA
11/2007
1Phosphotransferases (Kinase)IBA
11/2007
1Phosphates (Orthophosphate)IBA
09/2004
1Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
07/2004
1MitogensIBA
05/2002
1beta CateninIBA
04/2002
1Glucosamine (Dona)IBA
04/2002
1Insulin Receptor Substrate ProteinsIBA
04/2002
1N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime (PUGNAC)IBA
04/2002

Therapy/Procedure

1Glycemic Control
05/2016
1Lasers (Laser)
04/2014
1Therapeutics
04/2014